Delcath Systems (NASDAQ:DCTH) Trading Up 9.3% After Analyst Upgrade

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) rose 9.3% during mid-day trading on Monday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $16.46 and last traded at $16.51. Approximately 1,011,482 shares were traded during trading, an increase of 113% from the average daily volume of 475,969 shares. The stock had previously closed at $15.11.

A number of other research analysts have also weighed in on the company. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a report on Friday. HC Wainwright restated a “buy” rating and set a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research report on Friday. Finally, BTIG Research boosted their target price on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.17.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Zacks upgraded Delcath Systems from “Hold” to “Strong Buy,” reinforcing the stock’s recent momentum and potentially attracting additional buying interest. Zacks.com
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $32 price target while sharply raising its earnings forecasts. Its FY2026 EPS estimate improved to a loss of $0.17 from a loss of $0.88, and its FY2027 estimate moved to positive $0.12 from a loss of $1.23.
• Positive Sentiment: The longer-term outlook also improved materially: HC Wainwright raised projected EPS to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030. These revisions suggest expectations for accelerating profitability and support the analyst target’s implied upside.
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable earnings-estimate revisions. Separately, the average Wall Street price target indicates approximately 42.8% potential upside, although price-target reliability can vary. Zacks momentum stock article Zacks analyst price target article
• Neutral Sentiment: Reported short interest was listed at zero shares on both August 11 and July 27, with a zero-day short-interest ratio. Because the data shows no actual short position and includes an invalid “NaN” change, it provides little meaningful trading insight.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors have recently modified their holdings of DCTH. Nantahala Capital Management LLC purchased a new stake in shares of Delcath Systems in the 3rd quarter worth about $7,164,000. Marshall Wace LLP purchased a new position in Delcath Systems during the 2nd quarter valued at about $6,572,000. Rosalind Advisors Inc. increased its holdings in Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after acquiring an additional 400,000 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Delcath Systems by 116.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after acquiring an additional 315,583 shares during the last quarter. Finally, Lane Generational LLC acquired a new position in Delcath Systems during the fourth quarter worth about $1,997,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Down 1.7%

The company has a market cap of $587.45 million, a PE ratio of 1,696.40 and a beta of 0.52. The firm’s fifty day simple moving average is $12.61 and its 200-day simple moving average is $10.97.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The business had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. On average, analysts predict that Delcath Systems, Inc. will post -0.17 earnings per share for the current year.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.